Creo Medical Group plc was first admitted to the AIM Market of the London Stock Exchange in December 2016 with two subsequent fundraises to further develop IP and fully commercialise our products.
Procedures that previously took place in the operating room can now be undertaken in an endoscopy room, with material advantages in cost, time and patient outcomes.
Get the latest regulatory updates direct to your inbox
